meldonium | Cardionate capsules 250 mg, 40 pcs.
Special Price
$13.80
Regular Price
$24.00
In stock
SKU
BID464359
Release form
250 mg capsules.
10 capsules per blister pack of polyvinyl chloride film and aluminum foil. 100 capsules in polymer jars for medicines, sealed with caps.
A polymer jar or 2, 4 or 10 blister packs along with instructions for use in a pack of cardboard.
250 mg capsules.
10 capsules per blister pack of polyvinyl chloride film and aluminum foil. 100 capsules in polymer jars for medicines, sealed with caps.
A polymer jar or 2, 4 or 10 blister packs along with instructions for use in a pack of cardboard.
Release form
250 mg capsules.
10 capsules per blister pack of polyvinyl chloride film and aluminum foil. 100 capsules in polymer jars for medicines, sealed with caps.
A polymer jar or 2, 4 or 10 blister packs along with instructions for use in a pack of cardboard.
Packing
40 pcs.
Pharmacological action
Pharmacodynamics
Synthetic analog of gamma butyrobetaine, inhibits gamma butyrobetaine hydroxylase, reduces the synthesis of carnitine and the transport of long chain fatty acids through cell membranes, prevents the accumulation in the cells of activated forms of unoxidized fatty acids - derivatives of acylcarnitine and acylcoenzyme A. As a result of a decrease in carnitine concentration, gamma-butyrobetaine with vasodilating properties is intensely synthesized. In conditions of ischemia, meldonium restores the balance of the processes of oxygen delivery and its consumption in cells, prevents the violation of the transport of adenosine triphosphate (ATP): at the same time it activates glycolysis, which proceeds without additional oxygen consumption.
The mechanism of action determines the variety of pharmacological effects of meldonium: increased performance, decreased symptoms of mental and physical stress, activation of immunity, cardioprotective effect. In case of acute ischemic damage to the myocardium, it slows down the formation of the necrotic zone, shortens the rehabilitation period. With heart failure, it increases myocardial contractility, increases exercise tolerance: reduces the frequency of angina attacks.
In acute and chronic ischemic disorders of cerebral circulation, improves blood circulation in the focus of ischemia, promotes redistribution of blood in favor of the ischemic site.
Characteristic tonic effect on the central nervous system, elimination of functional disorders of the autonomic nervous system in patients with chronic alcoholism withdrawal syndrome.
Pharmacokinetics
After oral administration, it is rapidly absorbed from the gastrointestinal tract, bioavailability is 78%. The maximum concentration in blood plasma is reached after 1-2 hours. Metabolized in the body with the formation of two main metabolites, which are excreted by the kidneys. The elimination half-life depends on a dose and makes 3-6 hours.
Indications
Reduced performance mental and physical (including athletes) overload.
As part of complex therapy: coronary heart disease (angina pectoris), chronic heart failure, cardialgia on the background of dishormonal myocardial dystrophy.
As part of complex therapy: cerebrovascular accident (ischemic stroke, chronic cerebrovascular insufficiency).
Withdrawal symptoms in chronic alcoholism (as part of complex specific therapy).
Contraindications
Hypersensitivity to the main and / or auxiliary components of the drug increased intracranial pressure (with impaired venous outflow and intracranial tumors) pregnancy, breast-feeding period up to 18 years (efficacy and safety have not been established).
Caution
Chronic liver and / or kidney disease (due to insufficient data).
Special instructions
Caution should be exercised in the treatment of patients with chronic liver and kidney diseases, especially with prolonged use of the drug.
Insufficient data on use in children.
Influence on the ability to drive vehicles and mechanisms
There is no evidence of an adverse effect of the drug Kardionat® on the ability to drive vehicles and mechanisms.
Composition of
Per capsule: Active substance sdlkp (trimethylhydrazinium propionate dihydrate) in terms of dihydrate without adsorbed moisture - 250 mg.
Excipients
Potato starch 13.3 mg. silicon dioxide colloidal (aerosil) 5.7 mg. Calcium stearate 2.7 mg: capsule (gelatin, titanium dioxide).
Dosage and Administration
Inside. Capsules should be swallowed whole, washed down with water.
In view of the possible development of an exciting effect, the drug is recommended to be used in the morning.
Reduced performance, mental and physical stress - 500 mg (2 capsules) 2 times a day. The course of treatment is 10 to 14 days. If necessary, treatment is repeated after 2 to 3 weeks.
Athletes - 500 mg - 1.0 g (2 - 4 capsules) 2 times a day before training. The duration of the course in the preparatory period of training is 14 - 21 days, during the competition - 10 - 14 days.
Coronary heart disease (angina pectoris), chronic heart failure - 500 mg - 1.0 g (2-4 capsules) per day, using the entire dose at once or dividing it into 2 doses. The course of treatment is 4 to 6 weeks.
Cardialgia with dyshormonal myocardial dystrophy - 250 mg 2 times a day. The course of treatment is 12 days.
Disturbance of cerebral circulation.
In case of ischemic stroke - after the end of the 10-day course of therapy with the injectable form of the CardionatΠpreparation, the patient is transferred to the drug inside in capsules of 500 mg - 1.0 g (2-4 capsules) per day, taking the entire dose at once or dividing it into 2 doses . The general course of treatment is 4 to 6 weeks. In chronic cerebrovascular insufficiency - 500 mg (2 capsules) per day. The course of treatment is 2 to 3 weeks. The need for repeated courses of treatment (2-3 times a year) is determined by the doctor.
Withdrawal symptoms in chronic alcoholism - 500 mg (2 capsules) 4 times a day. The course of treatment is 7 to 10 days.
Side effects
From the cardiovascular system: tachycardia, decrease or increase in blood pressure.
From the gastrointestinal tract: dyspeptic phenomena.
From the central nervous system: arousal.
Allergic reactions: redness and itching of the skin, rash, swelling.
Other: eosinophilia, general weakness.
Drug Interactions
Can be combined with antianginal drugs, anticoagulants, antiplatelet agents. antiarrhythmic drugs and drugs and. diure geekam and. bronchodilators. Enhances the effect of coronary dilating, some antihypertensive drugs, cardiac glycosides. When combined with nitroglycerin, nifedipine, alpha-blockers. other antihypertensive drugs and peripheral vasodilators should be careful because of the possible development of moderate tachycardia and arterial hypotension.
Overdose
Symptoms: decreased blood pressure, accompanied by headache, tachycardia, dizziness, general weakness.
Symptomatic treatment.
Storage Conditions
In a dry place at a temperature not exceeding 25 РC.
Keep out of the reach and sight of children.
Expiration
3 years.
active substance
meldonium
lekarstvennaja form
kapsul
Nizhpharm, Russia
250 mg capsules.
10 capsules per blister pack of polyvinyl chloride film and aluminum foil. 100 capsules in polymer jars for medicines, sealed with caps.
A polymer jar or 2, 4 or 10 blister packs along with instructions for use in a pack of cardboard.
Packing
40 pcs.
Pharmacological action
Pharmacodynamics
Synthetic analog of gamma butyrobetaine, inhibits gamma butyrobetaine hydroxylase, reduces the synthesis of carnitine and the transport of long chain fatty acids through cell membranes, prevents the accumulation in the cells of activated forms of unoxidized fatty acids - derivatives of acylcarnitine and acylcoenzyme A. As a result of a decrease in carnitine concentration, gamma-butyrobetaine with vasodilating properties is intensely synthesized. In conditions of ischemia, meldonium restores the balance of the processes of oxygen delivery and its consumption in cells, prevents the violation of the transport of adenosine triphosphate (ATP): at the same time it activates glycolysis, which proceeds without additional oxygen consumption.
The mechanism of action determines the variety of pharmacological effects of meldonium: increased performance, decreased symptoms of mental and physical stress, activation of immunity, cardioprotective effect. In case of acute ischemic damage to the myocardium, it slows down the formation of the necrotic zone, shortens the rehabilitation period. With heart failure, it increases myocardial contractility, increases exercise tolerance: reduces the frequency of angina attacks.
In acute and chronic ischemic disorders of cerebral circulation, improves blood circulation in the focus of ischemia, promotes redistribution of blood in favor of the ischemic site.
Characteristic tonic effect on the central nervous system, elimination of functional disorders of the autonomic nervous system in patients with chronic alcoholism withdrawal syndrome.
Pharmacokinetics
After oral administration, it is rapidly absorbed from the gastrointestinal tract, bioavailability is 78%. The maximum concentration in blood plasma is reached after 1-2 hours. Metabolized in the body with the formation of two main metabolites, which are excreted by the kidneys. The elimination half-life depends on a dose and makes 3-6 hours.
Indications
Reduced performance mental and physical (including athletes) overload.
As part of complex therapy: coronary heart disease (angina pectoris), chronic heart failure, cardialgia on the background of dishormonal myocardial dystrophy.
As part of complex therapy: cerebrovascular accident (ischemic stroke, chronic cerebrovascular insufficiency).
Withdrawal symptoms in chronic alcoholism (as part of complex specific therapy).
Contraindications
Hypersensitivity to the main and / or auxiliary components of the drug increased intracranial pressure (with impaired venous outflow and intracranial tumors) pregnancy, breast-feeding period up to 18 years (efficacy and safety have not been established).
Caution
Chronic liver and / or kidney disease (due to insufficient data).
Special instructions
Caution should be exercised in the treatment of patients with chronic liver and kidney diseases, especially with prolonged use of the drug.
Insufficient data on use in children.
Influence on the ability to drive vehicles and mechanisms
There is no evidence of an adverse effect of the drug Kardionat® on the ability to drive vehicles and mechanisms.
Composition of
Per capsule: Active substance sdlkp (trimethylhydrazinium propionate dihydrate) in terms of dihydrate without adsorbed moisture - 250 mg.
Excipients
Potato starch 13.3 mg. silicon dioxide colloidal (aerosil) 5.7 mg. Calcium stearate 2.7 mg: capsule (gelatin, titanium dioxide).
Dosage and Administration
Inside. Capsules should be swallowed whole, washed down with water.
In view of the possible development of an exciting effect, the drug is recommended to be used in the morning.
Reduced performance, mental and physical stress - 500 mg (2 capsules) 2 times a day. The course of treatment is 10 to 14 days. If necessary, treatment is repeated after 2 to 3 weeks.
Athletes - 500 mg - 1.0 g (2 - 4 capsules) 2 times a day before training. The duration of the course in the preparatory period of training is 14 - 21 days, during the competition - 10 - 14 days.
Coronary heart disease (angina pectoris), chronic heart failure - 500 mg - 1.0 g (2-4 capsules) per day, using the entire dose at once or dividing it into 2 doses. The course of treatment is 4 to 6 weeks.
Cardialgia with dyshormonal myocardial dystrophy - 250 mg 2 times a day. The course of treatment is 12 days.
Disturbance of cerebral circulation.
In case of ischemic stroke - after the end of the 10-day course of therapy with the injectable form of the CardionatΠpreparation, the patient is transferred to the drug inside in capsules of 500 mg - 1.0 g (2-4 capsules) per day, taking the entire dose at once or dividing it into 2 doses . The general course of treatment is 4 to 6 weeks. In chronic cerebrovascular insufficiency - 500 mg (2 capsules) per day. The course of treatment is 2 to 3 weeks. The need for repeated courses of treatment (2-3 times a year) is determined by the doctor.
Withdrawal symptoms in chronic alcoholism - 500 mg (2 capsules) 4 times a day. The course of treatment is 7 to 10 days.
Side effects
From the cardiovascular system: tachycardia, decrease or increase in blood pressure.
From the gastrointestinal tract: dyspeptic phenomena.
From the central nervous system: arousal.
Allergic reactions: redness and itching of the skin, rash, swelling.
Other: eosinophilia, general weakness.
Drug Interactions
Can be combined with antianginal drugs, anticoagulants, antiplatelet agents. antiarrhythmic drugs and drugs and. diure geekam and. bronchodilators. Enhances the effect of coronary dilating, some antihypertensive drugs, cardiac glycosides. When combined with nitroglycerin, nifedipine, alpha-blockers. other antihypertensive drugs and peripheral vasodilators should be careful because of the possible development of moderate tachycardia and arterial hypotension.
Overdose
Symptoms: decreased blood pressure, accompanied by headache, tachycardia, dizziness, general weakness.
Symptomatic treatment.
Storage Conditions
In a dry place at a temperature not exceeding 25 РC.
Keep out of the reach and sight of children.
Expiration
3 years.
active substance
meldonium
lekarstvennaja form
kapsul
Nizhpharm, Russia
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review